ESC
Clarivate

 
Source: Journal Citation ReportsTM from ClarivateTM 2022

Entrepreneurship and Sustainability Issues Open access
Journal Impact FactorTM (2022) 1.7
Journal Citation IndicatorTM (2022) 0.42
Received: 2019-03-16  |  Accepted: 2019-12-20  |  Published: 2020-03-30

Title

Scientific priorities and real prospects for cost optimization in formulation development


Abstract

As a result of the systematic structural analysis of the collected scientific data on the problem under study, the trends in the development of the pharmaceutical sector that have established in the global space, including the Russian Federation, have been marked, the changes in the modern healthcare systems have been noted, and it has been proven that the problem of finding accelerated and efficient methods of drug development that meet the interests of all stakeholders needs the priority solution. The structure of distributing the clinical studies of drugs in the world practice has been presented, and data on the funds for the development of the main stages of the process under study and therapeutic groups of drugs for various nosologies have been presented. The main difficulties of objective assessment of the formulation development costs have been defined, the influencing factors have been identified, and the methodical approach to calculating the resources spent has been proposed. The results have been summarized, and the prospects for the rational use of the advanced information technologies for the development and support of innovative domestic developments in the pharmaceutical sector have been demonstrated. As a result of the research into the scientific data, a real opportunity to optimize the costs of developing innovative drugs through their repositioning has been demonstrated for the first time, the conceptual methodical approach to solving the identified problems has been justified, and prospects for its implementation have been outlined, with due consideration for the further development of the pharmaceutical market and the introduction of personalized pharmaceutical care. The study has been conducted on the basis of systematic analytical structuring of the information data and the results of independent research with the identification of global trends and the determination of practical significance, as well as scientific perspectives in the field under study.


Keywords

drug development, stages of development, efficiency of phases of clinical studies, capabilities of Artificial Intelligence in the development, cost optimization, repositioning of drugs


JEL classifications

O31


URI

http://jssidoi.org/jesi/article/470


DOI


Pages

1484-1499


This is an open access issue and all published articles are licensed under a
Creative Commons Attribution 4.0 International License

Authors

Glembotskaya, Galina T.
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation https://www.sechenov.ru
Articles by this author in: CrossRef |  Google Scholar

Eremin, Stanislav Yu.
I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation https://www.sechenov.ru
Articles by this author in: CrossRef |  Google Scholar

Chupandina, Elena E.
Voronezh State University, Voronezh, Russian Federation http://www.vsu.ru
Articles by this author in: CrossRef |  Google Scholar

Journal title

Entrepreneurship and Sustainability Issues

Volume

7


Number

3


Issue date

March 2020


Issue DOI


ISSN

ISSN 2345-0282 (online)


Publisher

VšĮ Entrepreneurship and Sustainability Center, Vilnius, Lithuania

Cited

Google Scholar

Article views & downloads

HTML views: 3043  |  PDF downloads: 1491

References